Maplelane Capital’s Allergan plc AGN Stock Holding History

Maplelane Capital’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-95,000	Closed	-$15.5M	–	198
2017 Q4	$15.5M	Sell	95,000 -135,000	-59%	-$24.2M	0.34%	67
2017 Q3	$47.1M	Buy	+230,000	New	+$53.5M	0.93%	30

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Maplelane Capital's AGN Position: Q1 2018 in Review

Maplelane Capital sold out of Allergan plc (AGN) in Q1 2018, closing a stake of 20,000 shares — an estimated $3.27M sold.

Maplelane Capital first reported a position in AGN in Q3 2013 and held it in 4 quarters. The position peaked at $3.27M in Q4 2017. 1,022 funds tracked by Wall St. Rank hold AGN as of Q1 2018.

Maplelane Capital reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
Maplelane Capital sold 20,000 Allergan plc shares in Q1 2018, an estimated $3.27M.
Maplelane Capital first reported a position in Allergan plc in Q3 2013 and held it in 4 quarters.
Maplelane Capital's Allergan plc position peaked at $3.27M in Q4 2017.
1,022 funds tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Maplelane Capital's 13F filing for Q1 2018, filed 15 May 2018.